9-cis-retinyl ester lipid formulations for retinal function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Leber congenital amaurosis, caused by defects in the retinoid cycle such as RPE65 deficiency, are limited in effectiveness and require development of stable formulations for visual chromophore replacement therapy.
Innovation Solution
Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle with a high percentage of polyunsaturated fatty acids, specifically 9-cis-retinyl acetate in soybean oil, are administered to bypass retinoid cycle blockades and regenerate functional chromophores in the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 9-cis-retinyl esters are administered to bypass retinoid cycle blockades, then visual function is improved, but formulation stability is compromised
Solution Approach 1:
The patent uses a lipid vehicle as an intermediary carrier to deliver 9-cis-retinyl esters. The lipid vehicle protects the sensitive retinyl esters from degradation while facilitating their delivery to the retina, thus resolving the contradiction between maintaining formulation stability and delivering the active compound for visual function improvement
Solution Approach 2:
The patent modifies the chemical parameters of the formulation by using specific lipid vehicles with controlled composition and properties. By changing the physical and chemical parameters of the delivery system (lipid vehicle selection, composition ratios), the formulation achieves both stability and efficacy in treating retinoid cycle blockades
2Reliability
If high concentration of 9-cis-retinyl esters is used to maintain visual function, then therapeutic efficacy is improved, but toxicity risk increases
Solution Approach 1:
The patent employs partial action by using the minimum effective concentration of 9-cis-retinyl esters required to maintain visual function. The lipid vehicle enables efficient delivery, allowing lower doses to achieve therapeutic effects, thus reducing toxicity risk while maintaining visual function
Solution Approach 2:
The lipid vehicle acts as a mediator that controls the release and distribution of 9-cis-retinyl esters, enabling therapeutic concentrations to be achieved at the target site (retina) while keeping systemic concentrations low, thereby maintaining efficacy and minimizing toxicity
Data Source
AI summary
Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.